Duchenne, a type of muscular dystrophy, may be the target of a new drug that is set to be manufactured and begun in phase 1 clinical trials.
Summit Corporation plc has secured 1 million pounds, or 1.5 million U.S. dollars from various charities to begin manufacturing the drug. The drug SMT C1100 basically increases a natural protein called Utrophin in the body which researchers believe will compensate for the lack of another similar structural compound, Dystrophin.
Mice trials showed that this new drug led to increased muscle strength and less tired muscles. Initial phase 1 trials showed a lack of full absorption into the blood stream, but the drug has been reformulated and is set for further phase 1 trials in the near future. A bright spot for those with Duchenne and possibly Becker muscular dystrophy they hope as well.